We are live on ! Find out more
ALT icon

Altimmune

25 hedge funds and large institutions have $1.32M invested in Altimmune in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% less ownership

Funds ownership: 0.29%0.28% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

4% less funds holding

Funds holding: 2625 (-1)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

16% less capital invested

Capital invested by funds: $1.57M → $1.32M (-$248K)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $2K

Holders
25
Holders Change
-1
Holders Change %
-3.85%
% of All Funds
0.57%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
4
Reduced
4
Closed
7
Calls
Puts
$2K
Net Calls
-$2K
Net Calls Change
-$2K
Name Holding Trade Value Shares
Change
Change in
Stake
IA
26
IFP Advisors
Florida
+$217 +11 New

ALT Hedge Fund Activity: Q2 2018 in Review

25 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q2 2018, worth a combined $1.32M — down 16% from $1.57M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ALT and 6 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.

The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $848K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $70.7K sold.

  • 25 institutional investors held Altimmune (ALT) as of Q2 2018, down from 26 in Q1 2018.
  • Funds reported $1.32M of Altimmune stock for Q2 2018, down 16% quarter-over-quarter.
  • 6 funds opened new Altimmune positions in Q2 2018 and 7 closed out, a net change of -1 holder.
  • The largest Altimmune buyer in Q2 2018 was Hudson Bay Capital Management, an estimated $848K added.
  • The largest Altimmune seller in Q2 2018 was Acadian Asset Management, an estimated $70.7K sold.

Based on aggregated 13F filings for Q2 2018.